Carbidopa / Levodopa / Entacapone Online

Buy Stalevo (Levodopa with Carbidopa and Entacapone) for Parkinson's disease
Cheap qualitative Carbidopa, Levodopa, Entacapone 25/100/200 mg tablets online



Lowest prices
Good quality
from $0.86 per pill
5% discount coupon: 5OFF


Low prices
High quality
from $1.12 per pill
5% discount coupon: dmeds5


Average prices
Best quality
from $1.39 per pill
5% discount coupon: MSD5


Carbidopa / Levodopa

The most common adverse reactions reported with carbidopa-levodopa have included dyskinesias, such as dystonic, choreiform, and other involuntary movements and nausea.

The following other adverse reactions have been reported with carbidopa-levodopa:

Body as a Whole: asthenia, chest pain.

Cardiovascular: hypotension, cardiac irregularities, orthostatic effects including orthostatic hypotension, syncope, hypertension, phlebitis, palpitation.

Gastrointestinal: gastrointestinal bleeding, dark saliva, development of duodenal ulcer, vomiting, anorexia, diarrhea, dyspepsia, constipation, dry mouth, taste alterations.

Hematologic: hemolytic and non-hemolytic anemia, agranulocytosis, thrombocytopenia, leukopenia.

Hypersensitivity: urticaria, angioedema, pruritus, Henoch-Schonlein purpura, bullous lesions (including pemphigus-like reactions).

Musculoskeletal: shoulder pain, back pain, muscle cramps.

Nervous System/Psychiatric: psychotic episodes including delusions, hallucinations, and paranoid ideation, bradykinetic episodes ("on-off" phenomenon), neuroleptic malignant syndrome, confusion, dizziness, agitation, somnolence, dream abnormalities including nightmares, insomnia, paresthesia, depression with or without development of suicidal tendencies, headache, dementia, increased libido. Convulsions also have occurred; however, a causal relationship with carbidopa-levodopa has not been established.

Respiratory: upper respiratory infection, dyspnea.

Skin: increased sweating, rash, alopecia, dark sweat.

Urogenital: urinary frequency, urinary tract infection, dark urine.

Laboratory Tests: abnormalities in alkaline phosphatase, SGOT (AST), SGPT (ALT), lactic dehydrogenase, bilirubin, blood urea nitrogen (BUN), Coombs' test; decreased hemoglobin and hematocrit; elevated serum glucose; white blood cells, bacteria, and blood in the urine.

Other adverse reactions that have been reported with levodopa alone and with various carbidopa-levodopa formulations, and may occur with Stalevo (Levodopa/Carbidopa/Entacapone) are:

Body as a Whole: fatigue, abdominal pain and distress.

Cardiovascular: myocardial infarction.

Gastrointestinal: dysphagia, gastrointestinal pain, sialorrhea, bruxism, flatulence, burning sensation of the tongue, hiccups, heartburn.

Metabolic: weight gain, edema, weight loss.

Musculoskeletal: leg pain.

Nervous System/Psychiatric: extrapyramidal disorder, ataxia, failing, anxiety, nervousness, gait abnormalities, decreased mental acuity, disorientation, memory impairment, euphoria, blepharospasm (which may be taken as an early sign of excess dosage; consideration of dosage reduction may be made at this time), increased tremor, trismus, numbness, activation of latent Horner's syndrome, muscle twitching, peripheral neuropathy.

Respiratory: cough, pharyngeal pain.

Skin: flushing, malignant melanoma.

Special Senses: diplopia, oculogyric crisis, blurred vision, dilated pupils.

Urogenital: urinary incontinence, urinary retention, priapism.

Miscellaneous: faintness, bizarre breathing patterns, hoarseness, hot flashes, malaise, sense of stimulation.

Laboratory Tests: increased serum creatinine and uric acid; decreased white blood cell count and serum potassium; protein and glucose in urine.


The most commonly observed adverse events ( > 5%) in the double-blind, placebo-controlled trials of entacapone (N=1003) associated with the use of entacapone alone and not seen at an equivalent frequency among the placebo-treated patients were: nausea, dyskinesia/hyperkinesia, urine discoloration, diarrhea, and abdominal pain.

Approximately 14% of the 603 patients given entacapone in the double-blind, placebo-controlled trials discontinued treatment due to adverse events compared to 9% of the 400 patients who received placebo. The most frequent causes of discontinuation in decreasing order are: diarrhea (2% vs. 0%), psychiatric reasons (2% vs. 1%), dyskinesia/hyperkinesia (2% vs. 1%), abdominal pain (1% vs. 0%), nausea (2% vs. 1%), and aggravation of Parkinson's disease symptoms (1% vs. 1%).

Adverse Event Incidence in Controlled Clinical Studies of Entacapone

Below are listed treatment emergent adverse events that occurred in at least 1% of patients treated with the ingredient of Stalevo entacapone participating in the double-blind, placebo-controlled studies and that were numerically more common in the entacapone group, compared to placebo. In these studies, either entacapone or placebo was added to carbidopa-levodopa (or benserazide-levodopa).

Summary of patients with adverse events after start of trial drug administration at least 1% in Entacapone group and > placebo

Skin and appendages disorders: sweating increased.

Musculoskeletal system disorders: back pain.

Central & peripheral nervous system disorders: hyperkinesia, dyskinesia, hypokinesia, dizziness.

Special senses, other disorders: taste perversion.

Psychiatric disorders: anxiety, somnolence, agitation.

Gastrointestinal system disorders: nausea, diarrhea, abdominal pain, constipation, vomiting, mouth dry, dyspepsia, flatulence, gastritis, gastrointestinal disorders NOS.

Respiratory system disorders: dyspnea.

Platelet, bleeding & clotting disorders: purpura.

Urinary system disorders: urine discoloration.

Body as a whole - general disorders: back pain, fatigue, asthenia.

Resistance mechanism disorders: bacterial infections.

The prescriber should be aware that these lists cannot be used to predict the incidence of adverse events in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical studies. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures do, however, provide the prescriber with some basis for estimating the relative contribution of drug and nondrug factors to the adverse events observed in the population studied.

Effects of Gender and Age on Adverse Reactions

No differences were noted in the rate of adverse events attributable to entacapone alone by age or gender.

Recent posts:

  • Buy Stalevo (Carbidopa, Levodopa, Entacapone) Online
  • Stalevo prescribing information

    Copyright © Buy Stalevo (Levodopa with Carbidopa and Entacapone) Online